Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Invested Capital (2016 - 2025)

Historic Invested Capital for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$139.2 million.

  • Ptc Therapeutics' Invested Capital rose 8656.07% to -$139.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.2 million, marking a year-over-year increase of 8656.07%. This contributed to the annual value of -$1.1 billion for FY2024, which is 3521.25% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Invested Capital stood at -$139.2 million, which was up 8656.07% from -$187.4 million recorded in Q2 2025.
  • Ptc Therapeutics' Invested Capital's 5-year high stood at $325.7 million during Q1 2021, with a 5-year trough of -$1.1 billion in Q4 2024.
  • Over the past 5 years, Ptc Therapeutics' median Invested Capital value was -$205.6 million (recorded in 2022), while the average stood at -$349.3 million.
  • Per our database at Business Quant, Ptc Therapeutics' Invested Capital plummeted by 52526.02% in 2023 and then surged by 8656.07% in 2025.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Invested Capital stood at $151.0 million in 2021, then crashed by 282.1% to -$274.9 million in 2022, then plummeted by 190.38% to -$798.4 million in 2023, then tumbled by 35.21% to -$1.1 billion in 2024, then skyrocketed by 87.1% to -$139.2 million in 2025.
  • Its Invested Capital was -$139.2 million in Q3 2025, compared to -$187.4 million in Q2 2025 and -$166.9 million in Q1 2025.